Cadila up 2% on USFDA nod for clinical trials of diabetes drug

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Moneycontrol Bureau

Cadila Healthcare shares rose nearly 2 percent intraday Monday after its group company has received approval from the US health regulator for clinical trials for diabetes drug.

"The US Food & Drug Administration has approved company's plan to initiate a phase 2 clinical trials of Saroglitazar (Lipaglyn) in patients with non-alcoholic steatohepatitis (NASH) of the liver in USA," the Ahmedabad-based pharma company says in its filing.

NASH is a liver disease in which fat accumulates in the liver.

Pankaj Patel, CMD of Zydus Cadila says NASH is an area of unmet healthcare and as there are currently no drugs approved for the treatment of NASH.

With a phase 3 trial in biopsy proven NASH patients ongoing in India and phase 2 trial planned in USA, the company is committed towards developing this drug for millions of patients suffering from NASH, he adds.

At 11:45 hours IST, the scrip of Cadila Healthcare was quoting at Rs 323.70, up Rs 4.00, or 1.25 percent on Bombay Stock Exchange.Posted by Sunil Shankar Matkar